Citations

Clear

1526 citation(s) found for "Sun, D".

Fibroblasts Exposed to Serum Collected After Long-Term Calorie Restriction Have Lower Mitochondrial Respiration
Seow, Lek Wei , Dozier, Stephen , Sun, Nina, Bergstrom, Jaclyn , LeBrasseur, Nathan K. , Molina, Anthony

Mayo Clinic

Innovation in Aging | January 3, 2026 | Volume: 9 | Issue: Supplement_2 | Pages: No page available

10.1093/geroni/igaf122.2543 Get It

Abstract Multiple lines of evidence suggest that calorie restriction may slow biological processes related to aging and extend lifespan. To determine whether calorie restriction affects mitochondrial function, we treated fibroblasts from adult donors with serum samples obtained from participants of the CALERIE (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy) study. The CALERIE study enrolled healthy, non-obese middle-aged (average 38y.o) participants to examine the effects of long-term calorie restriction. We studied the serum samples of 177 participants (calorie restriction CR = 121, ad libitum AL = 56) who had specimens available at two timepoints (12 and 24 months). We assessed the basal and maximal mitochondrial respiration of fibroblasts treated with dilute serum for 24 hours. Our results show that the baseline basal and maximal mitochondrial respiration of fibroblasts is positively correlated with the adiposity of the serum donor (R = 0.112, P = 0.137; R = 0.183, P = 0.015, respectively). Interestingly, treatment of fibroblasts with serum collected after 12 months of calorie restriction causes a decrease in both basal and maximal mitochondrial respiration (P = 0.1854; P = 0.0623, respectively). Fibroblasts treated with serum collected after 24 months of calorie restriction exhibited a further reduction in both basal and maximal mitochondrial respiration (P = 0.0174; P = 0.0092, respectively). These findings suggest that the serum of individuals on long term calorie restriction diet comprises factors that can reduce oxidative phosphorylation. This reduction in bioenergetic capacity may align with the theory that calorie restriction leads to a cellular energy-conserving state, which could have implications for cellular aging and metabolism.
Functional Evaluation of TRPC6 Missense Variants in Cancer Patients via Molecular Docking Analysis Compared with Patch Clamp Electrophysiology
Wu, Ying, SUN, XIAOJING , Reddy, Joseph S. , Advani, Pooja , Cerhan, J., Villarraga, Hector R, Asirvatham, Samuel J, Wang, R Y, Lee, H. C., Asirvatham, Samuel J. , Advani, Pooja P, Norton, Nadine , Asirvatham, Samuel J , Wu, Ying, Sun, Xiaojing, Boddicker, Nicholas , Cerhan, James R. , Villarraga, Hector R., Wang, Ru-Xing, Lee, Hon-Chi, Zanchi, Fernando Berton , Lu, Tong

Mayo Clinic

No container title available | January 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.01.697223 | PMID 41509376 Get It

ABSTRACT Gain-of-function mutations in the transient receptor potential 6 (TRPC6) channel have recently been recognized as risk factors for both doxorubicin (DOX)-induced cardiomyopathy. Functional evaluation of TRPC6 missense variants is therefore important for cancer patients undergoing anthracycline treatment. However, traditional electrophysiological methods are labor-intensive and time-consuming. In this study, we compared the functional responses of TRPC6 missense variants to 1-oleoyl-2-acetyl-sn-glycerol (OAG), a TRPC6 agonist, using molecular docking and patch clamp recording techniques. For the wild-type (WT) TRPC6 structure (PDB ID: 6UZ8), OAG exhibited a binding energy of -4.49 kcal/mol and a dissociation constant (Kd) of 0.511 mM. Twenty TRPC6 missense variants were identified from cancer patients in the Mayo Clinic database. Of these, fifteen variants had resolvable structures, nine of which displayed increased Kd values and six decreased Kd values compared to WT in molecular docking analysis. Patch clamp recordings revealed that TRPC6 WT and mutant channels were inactive at baseline but were activated upon 50 μM OAG stimulation, except two loss-of-function variants. Moreover, a 24-h treatment with 0.5 μM DOX significantly enhanced OAG-induced channel activation. All three variants identified in patients with heart failure demonstrated gain-of-function properties in both electrophysiological measurements and in-silico predictions. Importantly, the results obtained from molecular docking and patch clamp recordings were strongly correlated, showing an 82% concordance, higher than the predictions from AlphaMissense. These findings indicate that our computational analysis provides a rapid and reliable method for predicting the functional impact of TRPC6 missense variants, which may aid clinical decision-making in cancer patients receiving chemotherapy.
A conditional two‐step approach for detecting Lewy Body pathology: smell function testing and α‐synuclein seed amplification
Mastenbroek, Sophie E , Collij, Lyduine E., Caldera, Serena, Serrano, Geidy E, Adler, Charles, Vargiu, Claudia Marina , Palmqvist, Sebastian, Barkhof, Frederik, Beach, Thomas G, Hansson, Oskar H., Collij, Lyduine , Vogel, Jacob W. , Serrano, Geidy E. , Adler, Charles, Palmqvist, Sebastian , Barkhof, Frederik , Parchi, Piero , Beach, Thomas G. , Ossenkoppele, Rik , Hansson, Oskar

Mayo Clinic

Alzheimer's & Dementia | December 26, 2025 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_102894 Get It

Abstract Background Cerebrospinal fluid (CSF) seed amplification assays (SAAs) for detecting α‐synuclein (αsyn) seeds have recently emerged as robust in vivo biomarkers of Lewy body pathology (LBP). However, CSF sampling is invasive, costly, and time‐consuming, limiting its widespread use. We aimed to develop and evaluate a neuropathologically‐validated two‐step workflow, leveraging smell function and CSF αsyn SAA to accurately determine postmortem LBP status. This approach could reduce the number of confirmatory lumbar punctures needed (Figure 1). Methods The study included 358 individuals from the Arizona Study of Aging and Neurodegenerative Disorders with antemortem smell testing, CSF αsyn SAA results, and postmortem neuropathological assessments of regional LBP burden. Step‐1 of the two‐step workflow involved a risk‐stratification model predicting postmortem cortical LBP‐positivity (LBP ctx , defined as at least mild pathology in any cortical region) using logistic regression models with University of Pennsylvania Smell Identification Test (UPSIT) scores (smell testing), age, and sex as predictors. In step‐2, confirmatory CSF αsyn SAA testing was applied only to participants identified as high‐risk in step‐1. Workflow performance ‐ accuracy, positive predictive value (PPV), negative predictive value (NPV), and reduction in CSF testing ‐ was evaluated in (i) the entire study cohort; (ii) patients with clinical parkinsonism; (iii) patients with an Alzheimer's disease (AD) clinical syndrome; and (iv) clinically unimpaired (CU) individuals. Results Participants had a mean age at death of 86.2±7.8 years, 42.6% were female, 35.2% had LBP ctx , and the average time between UPSIT and death was 3.2±2.3 years (Table 1). Using a 95% sensitivity cut‐off for the UPSIT‐based algorithm, the two‐step workflow achieved high accuracy in identifying LBP ctx (whole cohort=94%; clinical parkinsonism=95%; clinical AD=94%; CU=93%; Figure 2a), while reducing CSF testing (whole cohort=‐43%; clinical parkinsonism=‐23%; clinical AD=‐35%; and CU=‐80%; Figure 2d). PPVs ranged from 75‐96% and were highest in the clinical parkinsonism subgroup (96%) where LBP ctx + was highest (62.7%). NPVs ranged between 95‐98% and were highest in the clinical AD subgroup (98%) (Figure 2b‐c). The two‐step approach reached accuracies similar to using CSF tests in all participants. Conclusions Implementing a two‐step workflow in different clinical scenarios may reduce invasive testing with CSF, minimizing the burden for individuals and costs for healthcare providers.
T cells use TNF and IFNγ for paracrine killing with target discrimination programmed by pathogen-derived factors
Guttormson, Matthew C. , Krogman, Erica N., Carr, Allison R. , Rizzo, Skylar A. , Muske, Josey , Ziaee, Maia , Therrien, Nicholas R. , Sun, N , Ghale, Romina , Medlyn, Michael J. , Billadeau, Daniel D. , Pease, Larry R. , Ting, Adrian T. , Rizzo, Skylar A , Sun, Nicholas D , Knoop, Kathryn A.

Mayo Clinic

No container title available | December 26, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2025.12.23.696308 Get It

ABSTRACT Cytotoxic T lymphocytes (CTLs) are known to eliminate target cells through perforin-mediated, contact-dependent killing - a process limited by the number of effector T cells despite its serial nature. CTLs likely also possess a mass killing mechanism that can eliminate target cells more efficiently. Using CAR-T cells against B7H3 present on B16 tumor targets, we demonstrate that activated T cells can also kill targets in a perforin-independent manner by releasing diffusible TNF and IFNγ capable of killing nearby targets in a paracrine fashion even if they bear no antigen. Against an unperturbed target, paracrine killing is inefficient but is enhanced by the deletion of TNFR1 signaling molecules such as TAK1, HOIP, or TBK1/IKKε. Notably, these molecules are inhibited naturally by pathogen-encoded antagonists. Expression of a microbial-encoded antagonist, such as the Yersinia -encoded YopJ that antagonizes TAK1 or Ebola-encoded VP35 that antagonizes TBK1/IKKε, alters the target cell response to these cytokines from non-lethal to lethal. We propose that target cells are inherently resistant to killing by TNF and IFNγ, but the presence of a microbial factor alters this sensitivity, providing for the selective elimination of the infected cell while minimizing harm to uninfected bystander cells. We propose the term ‘pathogen-restriction’ to describe this discriminatory mechanism. Potentially, any microbial-derived factor that crosstalks with the TNF and IFNγ signaling pathways can function as a pathogen-restriction element. GRAPHICAL ABSTRACT Short Summary T cells use TNF and IFNγ to kill target cells in a paracrine manner where target elimination is restricted by the presence of pathogen-derived factors.
Amygdala gene alterations in Parkinson's disease
Aslam, Sidra, Walker, Jessica E. , Intorcia, Anthony J., Adler, Charles, Shill, H. A., Mehta, SH, Driver‐Dunckley, E. D., Atri, A., Beach, Thomas G, Serrano, Geidy E, Zeighami, Yashar, Tremblay, Cécilia , Frosi, Gabriella , Choudhury, Parichita , Adler, Charles, Shill, Holly A. , Mehta, Shyamal H. , Nagy, Corina , Driver‐Dunckley, Erika , Beach, Thomas G. , Serrano, Geidy E. , Zeighami, Yashar

Mayo Clinic

Alzheimer's & Dementia | December 24, 2025 | Volume: 21 | Issue: S1 | Pages: No page available

10.1002/alz70855_106020 Get It

Abstract Background The amygdala is closely connected to the olfactory bulb and involved in olfactory processing as well. It is a particularly susceptible region that accumulates a‐synuclein pathology in Parkinson's disease (PD). Our previous work revealed olfactory bulb gene alterations related to neuroinflammation, and neurotransmitter dysfunction to be associated with olfactory function. We aimed to extend this work and assess gene expression changes, affected pathways and co‐expression networks by transcriptomic profiling of the amygdala in subjects with and without clinicopathologically defined PD. Method Bulk RNA sequencing was performed on frozen human amygdala of 20 PD and 20 controls without dementia or any other neurodegenerative disorder, from the Arizona Study of Aging and Neurodegenerative Disorders. Result Differential expression analysis, corrected for age, sex and post‐mortem interval revealed 40 significantly differentially expressed genes (DEGs) in PD. Downregulated genes were mainly related to altered hemoglobin expression while upregulated genes included inflammatory markers and glutamine transporter. Significantly enriched pathways were involved in oxygen and carbon dioxide transport, cellular oxidant detoxification and regulation of glutamine secretion. Cell enrichment revealed these genes to be mainly expressed in neurons. Co‐expression network analysis using Weighted correlation network analysis (WGCNA ) subsequently identified four significant modules correlated with both PD and premortem olfactory dysfunction which were involved in pathways related to neuroinflammatory processes, mitochondrial, endoplasmic reticulum and lysosomal dysfunction. Conclusion These preliminary results suggest cellular alterations in the amygdala related to mitochondrial dysfunction, altered oxygen homeostasis, oxidative stress, inflammation as well as glutamatergic neurotransmitter dysfunction that may contribute to neurodegeneration in PD.
A resource of data and samples in cognitively unimpaired persons at six levels of Alzheimer's disease risk based on their APOE genotype
Ghisays, Kathryn L., Brostrom, Deborah, Bauer, Robert, Devadas, Vivek, Salata, Hayley, Brown, Christopher , Walsh, Trisha, Liang, Winnie, Ashton, Nicholas, Geda, Yonas E., Huentelman, Matthew J. , Pruzin, Jeremy J. , Su, Yi, Caselli, Richard J., Woodruff, Bryan K. , Reiman, Eric M., Ghisays, Valentina , Geda, Yonas E. , Su, Yi, Caselli, Richard J. , Langbaum, Jessica B. S. , Reiman, Eric M.

Mayo Clinic

Alzheimer's & Dementia | December 24, 2025 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_102172 Get It

Abstract Background Apolipoprotein E (APOE), the major genetic risk factor for Alzheimer's disease (AD), has three common alleles (2, 3 and 4), giving rise to genotypes that are associated with six levels of AD risk: (2/2<2/3<3/3<2/4<3/4<4/4). In our new Arizona APOE Cohort Study, we have begun to establish a longitudinal cohort of more than 300 cognitively unimpaired persons (50‐90 year‐old) stratified by APOE genotype and age decile, matched by age and sex, and have an extensive battery of cognitive, clinical, amyloid (NAV4694) and tau (MK6240) PET, MRI, cerebrospinal fluid (CSF), plasma, and DNA. The study is intended to clarify the impact of APOE4 and APOE2 allelic dose on the predisposition to and protection from AD and inform the design of secondary and primary prevention therapies. Here, we describe the study and the resource of data and samples that are now available to researchers. Methods Participants were recruited from across the United States using GeneMatch and other sources. Comprehensive clinical assessments, brain images, and lumbar punctures are performed every 2 years, 50mL blood samples are acquired annually, and whole genome sequencing is in progress. Results As of January 2025, baseline assessments were completed in 303 participants, 68±9 years of age, including 205 females and 98 males. Sixteen percent are from underrepresented groups. Baseline CSF samples were obtained in 89% of the participants. The complete cohort consists of 17, 63, 41, 65, 66, and 51 persons with the APOE 2/2, 2/3, 3/3, 2/4, 3/4, and 4/4 genotype, respectively. In the first 287 participants with available amyloid PET scans 6% of 2/2, 5% of 2/3, 14% of 3/3, 26% of 2/4, 29% of 3/4, and 52% of 4/4 participants had a positive amyloid PET (≥20 centiloids). Conclusions Building up on our decades of experience in APOE research, we launched the new Arizona APOE Cohort which promises to provide a valuable resource of data and samples to advance the study of APOE, its variants and interactions with other risk and protective factors, and the development, treatment, and prevention of AD. Baseline data are now available to interested and eligible research collaborators.
A unique pattern of T2 FLAIR white matter hyperintensities and related co‐localizing neuropathology associated with repetitive head impacts
Groh, Jenna R., Miner, Annalise E. , Alshikho, Mohamad J. , Tripodis, Yorghos, Cui, Anna, Adler, Charles, Balcer, Laura J. , Bernick, Charles , Coleman, Michael J., Dodick, David W., McKee, Ann C., Mez, Jesse, Bouix, Sylvain, Cummings, Jeffrey L., Reiman, Eric M., Shenton, Martha E., Stern, Robert A., Stein, Thor D., Alosco, Michael L. , Groh, Jenna R. , Farris, Chad W. , Brickman, Adam M. , Tripodis, Yorghos , Cui, Anna, Adler, Charles, Cantu, Robert C. , Coleman, Michael J. , Dodick, David W. , McKee, Ann C. , Mez, Jesse , Bouix, Sylvain , Reiman, Eric M. , Shenton, Martha E. , Stein, Thor D.

Mayo Clinic

Alzheimer's & Dementia | December 24, 2025 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_096739 Get It

Abstract Background Chronic traumatic encephalopathy (CTE) is a neurodegenerative tauopathy associated with repetitive head impacts (RHI). Autopsy studies show that RHI influences risk for other later‐life neuropathologies, particularly white matter and vascular injury. We have observed a unique pattern of white matter hyperintensities (WMH) on FLAIR MRI in people exposed to RHI (RHI‐WMH) characterized by small, discrete lesions near the depths of sulci (Figure 1a). The objective of this study was to characterize this pattern empirically in former American football players and to investigate neuropathology co‐localizing with the WMH. Method The sample included 164 male former football players ( n = 111 professional, n = 53 college) and 55 asymptomatic males without RHI from the DIAGNOSE CTE Project (Table 1). Visual ratings of WMH blind to the participant's RHI and clinical status were conducted to count lesions that were a.) within 1.0cm of the gray/white matter boundary, b.) as bright as the cortex, c.) spherical and d.) <1.0cm in size. ANCOVA compared groups on total number of WMH adjusted for age and vascular risk factors. We selected one individual (former professional player) with the typical RHI‐WMH pattern and who donated their brain for neuropathological examination. Guided by in vivo MRI, ex vivo MRI was done to locate the WMH near the depths of the sulci in the tissue. Tissue sections were tested for phosphorylated tau immunoreactivity and reactive astrocytes and microglia in areas surrounding the lesion seen on MRI. Result Number of RHI‐WMH was greater in football players compared to controls ( p = 0.007) (Figure 1b). Number of RHI‐WMH was greater in former professional players compared to controls ( p = 0.001) but not compared to the college players ( p = 0.983). In the neuropathology case study, we located the punctate RHI‐WMH on ex vivo MRI. Immunostaining revealed that the RHI‐WMH was adjacent to a sulcus with the pathognomonic CTE p ‐tau lesion and was characterized by myelin pallor, dense GFAP‐positive glial scarring, and increased total and activated microglia (Figure 2). Conclusion We provide empirical support for exposure to RHI as potentially leading to a unique pattern of WMH. Importantly, histopathological evidence showed that the RHI‐WMH co‐localized with RHI and CTE‐related neuropathologies at the depths of the sulci.
Imaging‐neuropathology evaluation of Amyloid Related Imaging Abnormality sulcal effusion in a DIAN‐TU‐001 participant treated with gantenerumab
Joseph‐Mathurin, Nelly, Chen, Charles D., Flores, Shaney, Scott, Jalen , Anand, Sanjana, Franklin, Erin E., Lu, Ruijin , Gordon, Brian A., Jack, C. R., Cruchaga, Carlos C, Hassenstab, Jason J., Ibanez, Laura, Li, Yan, Wang, Guoqiao, Renton, Alan E., Xiong, Chengjie, Atri, A., Snider, B. Joy, Clifford, David B., Bateman, Randall J., Wang, Q., Perrin, Richard J., Benzinger, Tammie L.S., Jack, Clifford R. , Jack, Clifford R , Joseph‐Mathurin, Nelly , Hobbs, Diana A. , Jiang, Meng, Flores, Shaney , Franklin, Erin , Gordon, Brian A. , Cruchaga, Carlos , Ibanez, Laura , Wang, Guoqiao , Renton, Alan , Xiong, Chengjie , Snider, B. Joy, Llibre‐Guerra, Jorge J. , Clifford, David B. , McDade, Eric , Bateman, Randall J. , Perrin, Richard J. , Benzinger, Tammie L.S.

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S8 | Pages: No page available

10.1002/alz70862_110062 Get It

Abstract Background Amyloid related imaging abnormality edema (ARIA‐E) occurs in about 19% of individuals with autosomal dominant Alzheimer disease (ADAD) treated with an anti‐amyloid‐b monoclonal antibody (Salloway et al., 2021). In a previously reported case, ARIA‐E appeared to colocalize with decreases in PiB‐PET uptake (Joseph‐Mathurin, Llibre‐Guerra, et al, 2022), suggesting an association between amyloid‐b (Aβ) removal and ARIA‐E. Here, we compare longitudinal neuroimaging and corresponding neuropathology in an ADAD individual treated with gantenerumab, who experienced multiple ARIA‐E episodes as sulcal effusions that resolved by the end of the four‐year trial. Methods PiB‐PET and MRI were collected pre‐ and post‐randomization (2 and 4 years). The participant consented to brain donation, which was received a year after trial completion. Four tissue samples were taken from the location of the ARIA‐E in the parieto‐occipital left hemibrain as identified by MRI (one block contained the sulcus affected by ARIA‐E; the rest of the coronal section was captured in the remaining three blocks). Area fractions (AFs) of Aβ (10D5 immunohistochemistry (IHC)), tauopathy (PHF1), microglia (Iba1), and astrocytes (GFAP) in one sulcal region of interest (ROI) from each block and PiB‐PET SUVRs of corresponding ROIs were extracted ( n = 4, Figure 1). Additionally, we included PiB‐PET SUVRs corresponding to ARIA‐E findings observed in the right hemisphere at baseline, two‐year, and four‐year visits ( n = 6). Results Overall PiB‐PET uptake increased during the first two years (before ARIA‐E) and decreased during the last two years (including ARIA‐E episodes) (0.03±0.05 vs. ‐0.04±0.04 SUVR/year, p ‐value=0.01, Figure 2). The decrease seemed more pronounced in ARIA‐E ROIs versus normal‐appearing sulcus ROIs (‐0.05±0.04 vs. ‐0.02±0.03 SUVR/year). Lower PiB uptake at last visit appeared associated with lower Aβ AF (estimates=0.03±0.01, p ‐value=0.07). The ARIA‐E ROI had an Aβ AF of 0.009 while normal‐appearing sulcus ROIs had a mean of 0.02+0.003 (Figure 3). AFs for tauopathy, microglia, and astrocytes were within the range of those of normal‐appearing sulcus ROIs, suggesting an Aβ‐specific effect, although unexamined markers may play a role. Conclusions Our preliminary findings indicated that ARIA‐E is associated with longitudinal PiB‐PET decrease and Aβ AF, supporting the link between ARIA‐E, changes in PiB‐PET, and local Aβ removal observed at autopsy. Funding : K01AG080123; U01AG042791; R01AG046179; R01AG053267
Every Centiloid, from Everywhere, All at Once
Snyder, Heather M. , Apostolova, Liana G., Bombois, Stéphanie, Bourgeat, Pierrick, Braskie, Meredith N. , Carrillo, Maria, Casaletto, Kaitlin B, Chang, C. -C., Chang, Hsin‐I., Chao, Yishu , Chetelat, Gaël, Collij, Lyduine E., Dickerson, Brad C., Dubois, Bruno, Valdez, Alfonso Fajardo, Farrar, Gill , Fortea, Juan M., Frisoni, Giovanni B, Gu, Yuna , Guo, Tengfei, Hansson, Oskar H., Huang, Q., Huang, Shu‐Hua , Ishii, Kenji, Jagust, William J., Kato, Takashi , Koeppe, R. A., Kramer, Joel H, Landau, Susan M., Landeau, Brigitte, Lee, Sangwon, Lopresti, Brian J. , Lowe, Val J. , Mao, Xiaoxie, March, Andrew, Masters, Colin L., Mézenge, Florence, Mormino, Elizabeth C. , Franquesa‐Mullerat, María , Nakamura, Akinori, O'Bryant, Sid E., Pappas, Ioannis G., Rowe, C. C., Schott, Jonathan M, Schwartz, Daniel L. , Schwarz, Christopher G, Seo, Sang Won, Shekari, Mahnaz, Smith, Ruben, Sokołowski, Andrzej , Soleimani‐Meigooni, David, Sperling, Reisa A., Sun, Pan , Toga, Arthur W., Vaillancourt, David E. , Flier, Wiesje M. van der, Vemuri, Prashanthi, Villain, Nicolas , Villemagne, Victor L., Villeneuve, Sylvia , Wang, Wei‐En, Weiner, Michael S. W., Xiao, Cally , Xie, Fang, Yoon, Yeojun, Yun, M R , Rabinovici, Gil D., Wang, Wei‐en , Blazhenets, Ganna , Apostolova, Liana G. , Asken, Breton M. , Bejanin, Alexandre , Bombois, Stéphanie , Bourgeat, Pierrick , Casaletto, Kaitlin B. , Cash, David M. , Chang, Hsin‐I , Chételat, Gaël , Coath, William , Collij, Lyduine , Colmant, Lise , Dickerson, Brad C., Dubois, Bruno , Fortea, Juan , Frisoni, Giovanni B. , Gardner, Raquel C. , Garibotto, Valentina , Guo, Tengfei , Hanseeuw, Bernard , Hansson, Oskar , Harrison, Theresa M. , Ishii, Kazunari , Jagust, William J. , Kramer, Joel H. , Landau, Susan, Landeau, Brigitte , Masters, Colin L. , Mézenge, Florence, Nakamura, Akinori , O’Bryant, Sid E. , Peretti, Débora Elisa , Quenon, Lisa , Salvadó, Gemma , Schott, Jonathan M. , Schwarz, Christopher G. , Seo, Sang Won , Shekari, Mahnaz , Silbert, Lisa C. , Sokolowski, Andrzej, Soleimani‐Meigooni, David N. , Sperling, Reisa Anne , Sun, Pan , Toga, Arthur W. , Giessen, Elsmarieke van de , Flier, Wiesje M. van der , Vemuri, Prashanthi , Villemagne, Victor L. , Weiner, Michael W. , Xie, Fang , Young, Christina B. , Rabinovici, Gil D. , Joie, Renaud La

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S8 | Pages: No page available

10.1002/alz70862_110011 Get It

Abstract Background Ten years after the original publication, the Centiloid framework is now broadly used to harmonize amyloid‐PET quantification, facilitate data sharing and comparison across cohorts, and even assist visual interpretation in clinical settings. We evaluated the global implementation of Centiloids by comparing their distribution and corresponding positivity thresholds across cohorts. Methods We gathered data from publicly available cohorts and reached out to investigators across the world to collect cross‐sectional Centiloids, demographic and clinical information, and visual read data. Gaussian mixture models (GMM, k=2) were fitted to Centiloid values for each cohort and cutoffs were calculated as mean + 2SD of the lower Gaussian. When visual reads were available, we determined Centiloid cutoffs that maximized correspondence with visual reads (Cohen’s kappa). Data was combined across cohorts using random effects meta‐analyses. Results As of January 2025, we included 37 cohorts ( n = 41,678 participants) with heterogeneous pipelines, radiotracers, and clinical and demographic characteristics (Table‐1). The low Gaussian peaks ranged from ‐9 to 10CL; the meta‐analysis identified a common peak at 1CL. The second peaks were more heterogeneous (range=38‐102CL; meta‐analysis outcome=64CL). Across cohorts, the proportion of cognitively unimpaired versus impaired participants impacted the position of both peaks, with better separation in cohorts enriched in impaired individuals (Figure‐1C). The meta‐analysis indicated a GMM‐based cutoff of 19CL (95%CI: 16‐21CL, Figure‐1B); subgroup analyses showed no evidence of significant effect between single versus multicenter settings (17 versus 20CL, p = 0.30), MRI‐based or PET‐only processing (18 versus 19CL, p = 0.88), and no evidence of difference across radiotracers (Flutemetamol: 16CL; PIB: 17CL, Flutafuranol: 18CL, Florbetaben: 19CL, Florbetapir: 20CL, p = 0.78). In a subset of 29,496 participants with visual reads available, binary visual reads corresponded well to Centiloids (common kappa=0.86, Figure‐2A). The visual read‐based cutoff of 24CL (95%CI: 21‐27CL, Figure‐2B) maximized correspondence between visual read and quantification and was slightly higher than the GMM‐based cutoff. All meta‐analysis models showed high non‐random heterogeneity (I 2 >80%) across studies, suggesting non‐random differences in peaks and cutoffs. Conclusions Meta‐analysis‐based cutoffs align well with thresholds from the existing literature. High heterogeneity among studies underscores the need to investigate contributing factors, raising concerns about applying common cutoffs.
Immuno‐Regulation of Brain Region‐Specific Organoids Containing Isogenic Microglia‐Like Cells
Ene, Justice , Lü, Wenyan, Syed, Falak, Ren, Yi , Kanekiyo, Takahisa , Li, Yan , Li, Yan , Liu, Chang , Syed, Falak, Sun, Li , Raulin, Ana‐Caroline , Wang, Xueju Sophie

Mayo Clinic

Advanced Healthcare Materials | December 18, 2025 | Volume: 15 | Issue: 10 | Pages: No page available

10.1002/adhm.202503579 | PMID 41408986 Get It

ABSTRACT Most brain organoids derived from human induced pluripotent stem cells (iPSCs) lack microglia and thus immune function. Microglia‐like cells (MGCs) can be differentiated from iPSCs, while the characteristics of isogenic MGC‐containing brain organoids in modeling neurodegeneration and cell‐cell communications have not been well investigated. In this study, iPSC‐derived MGCs are co‐cultured with isogenic forebrain cortical organoids (iFCo), which are stimulated with extracellular vesicles (EVs) of brain organoids differentiated from Alzheimer's disease (AD) patient‐derived iPSCs ( APOE ε4/ε4 and presenilin 1). The AD EV‐stimulated co‐culture organoids are treated with EVs from healthy MGCs or co‐culture. Differential responses of the co‐cultured organoids and the MGCs to AD EVs are demonstrated. The co‐cultured organoids mitigated pro‐inflammatory gene expressions. EVs from healthy MGCs or co‐culture reduced the expression of IL‐12β , iNOS , TREM2 , and CASS4 , which are associated with neural inflammation and degeneration, as well as showed regulation on genes involved in microglial activation and carbon metabolism. AD EV cargo analysis by proteomics and microRNA‐sequencing revealed APOE and APP proteins and microRNAs regulated pathways such as mitophagy. This study paves the way for understanding the role of microglia and brain organoids in modeling neural degeneration and the development of EV‐based cell‐free therapeutics for AD treatment.